Overview
- 40 inspections across 38 sites are on record.
- 64 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-04-27.
About Alan Rivera
Alan A Rivera, who also appears on FDA documents as Alan Rivera, is an FDA investigator whose record on Atlas runs from April 2022 to April 2026: 40 inspections at 38 sites and 64 Form 483 observations. Nineteen of the 20 Form 483s in the published record are for human drug facilities; one is for an animal drug manufacturer.
Most of the work is in Puerto Rico. Nine of the 20 Form 483s went to facilities in San Juan, Gurabo, Caguas, Carolina, Juncos, Humacao and Manati, including Amgen Manufacturing in Juncos and Gasco Industrial in Gurabo, which received a 483 in both 2022 and 2023. Five went to Indian facilities, among them Amneal Pharmaceuticals in Palli, Concord Biotech and Stallion Laboratories in Ahmedabad, and OneSource Specialty Pharma in Bengaluru.
The forms are short: 3.2 observations on average, seven at most. The regulation cited most is 21 CFR 211.100(a), written production and process control procedures, followed by 211.192 investigations and 211.22(d) quality unit procedures. Alan Rivera most often inspects with Marian E Ramirez, who co-signed nine of the 20 forms, and Angelica M Hernandez, who co-signed six. For what a 483 is and what follows one, see what an FDA Form 483 is.
At a glance
Inspections
40
Sites
38
Observations
64
Career since
Apr 2022
Form 483s on record
Every Form 483 in the published record that names Alan A Rivera, most recent first.
| Issued | Company and facility | Category | Observations |
|---|---|---|---|
| 7 Oct 2025 | Materials Characterization Center IncSan Juan, United States | Human Drugs | 1 |
| 11 Sep 2025 | Oxygen Development, L.L.C.Palm Springs, United States | Human Drugs | 3 |
| 27 Jun 2025 | Procter & Gamble Manufacturing Mexico, S. de R.L. de C.V.Naucalpan, Mexico | Human Drugs | 2 |
| 16 May 2025 | A.I.G Technologies Inc.Deerfield Beach, United States | Human Drugs | 5 |
| 28 Mar 2025 | ONESOURCE SPECIALTY PHARMA LIMITEDBengaluru, India | Human Drugs | 4 |
| 19 Mar 2025 | Amneal Pharmaceuticals Private LimitedPalli, India | Human Drugs | 4 |
| 17 May 2024 | V-Ensure Pharma Technologies Pvt LimitedChipley Village, India | Human Drugs | 2 |
| 23 Feb 2024 | Medipharm Laboratories, IncMiami, United States | Human Drugs | 2 |
| 11 Jan 2024 | Custom Manufacturing CorporationMedley, United States | Animal Drugs & Feeds | 7 |
| 8 Dec 2023 | Gasco Industrial Corp.Gurabo, United States | Human Drugs | 7 |
| 23 Oct 2023 | Omega & Delta Co., Inc.Carolina, United States | Human Drugs | 3 |
| 21 Sep 2023 | Richard E. Colgin, IncDallas, United States | Human Drugs | 5 |
| 5 Jul 2023 | Amgen Manufacturing Limited LLCJuncos, United States | Human Drugs | 3 |
| 31 May 2023 | Auro PR Inc.Caguas, United States | Human Drugs | 2 |
| 24 Mar 2023 | Stallion Laboratories Private LimitedAhmedabad, India | Human Drugs | 2 |
| 17 Mar 2023 | CONCORD BIOTECH LIMITEDAhmedabad, India | Human Drugs | 2 |
| 20 Jan 2023 | Galephar Pharmaceutical Research Inc.Humacao, United States | Human Drugs | 2 |
| 18 Oct 2022 | Gasco Industrial Corp.Gurabo, United States | Human Drugs | 5 |
| 12 Jul 2022 | Patheon Puerto Rico, Inc.Manati, United States | Human Drugs | 2 |
| 1 Apr 2022 | NEOLPHARMA, INC.Caguas, United States | Human Drugs | 1 |
Regulations cited most
How many of Alan A Rivera's Form 483s cite each section of the Code of Federal Regulations.
| Regulation | What it covers | Form 483s citing it |
|---|---|---|
| 21 CFR 211.100(a) | Written production and process control procedures | 4 |
| 21 CFR 211.192 | Production record review and investigation of discrepancies | 3 |
| 21 CFR 211.22(d) | Responsibilities of the quality control unit | 3 |
| 21 CFR 211.188(b)(11) | Batch production and control records | 1 |
| 21 CFR 211.160(b) | Laboratory controls, general requirements | 1 |
| 21 CFR 211.194(a)(4) | Laboratory records | 1 |
| 21 CFR 211.113(b) | Control of microbiological contamination | 1 |
| 21 CFR 211.42(c) | Design and construction of facilities, including aseptic processing areas | 1 |
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Amgen Manufacturing Limited LLC | 27 Apr 2026 | Human Drugs | On file |
| Maiva Pharma Private Limited | 20 Feb 2026 | Human Drugs | On file |
| BioMylz Pvt. Ltd. | 9 Feb 2026 | Human Drugs | On file |
| Global Calcium Pvt. Limited | 3 Feb 2026 | Human Drugs | On file |
| Alchymars ICM SM Private Limited | 4 Dec 2025 | Human Drugs | On file |
Sites inspected
Co-investigators
Investigators who co-signed a Form 483 with Alan A Rivera.
- Marian E Ramirez9 shared 483s
- Angelica M Hernandez6 shared 483s
- Anastasia M Shields2 shared 483s
- Jose F Velez2 shared 483s
- Dorothy P Kramer1 shared 483
- Megan T Ziegler1 shared 483
- Ivis L Negron Torres1 shared 483
- Ariel Cruz Figueroa1 shared 483
Full investigator report
Get the verbatim findings behind Alan A Rivera's 64 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site